A clinical predictor score for 30-day mortality among HIV-infected adults hospitalized with pneumonia in Uganda

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Koss, Catherine A ^a   Jarlsberg, Leah G ^b   Den Boon, Saskia ^c   Cattamanchi, Adithya ^b,c   Davis, J Lucian ^b,c   Worodria, William ^c,d,e   Ayakaka, Irene ^c   Sanyu, Ingvar ^c   Huang, Laurence ^a,b,c   Davis, Lucian ^f   Andama, Alfred ^f   Byanyima, Patrick ^f   Kalema, Nelson ^f   Katagira, Winceslaus ^f   Awor, Margaret ^f   Kaswabuli, Sylvia ^f   Nabakiibi, Catherine ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAKERERE UNIVERSITY   (Uganda)

^d MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^e Mulago National Referral and Teaching Hospital   (Uganda)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; OXYGEN;

ADULT; ARTICLE; BREATHING RATE; BRONCHOSCOPY; CD4 LYMPHOCYTE COUNT; COUGHING; DISEASE DURATION; FEMALE; FUNGUS CULTURE; HEART RATE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MYCOBACTERIUM; OXYGEN SATURATION; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PREDICTION; PROSPECTIVE STUDY; REGRESSION ANALYSIS; RISK ASSESSMENT; SECONDARY ANALYSIS; SPUTUM ANALYSIS; SPUTUM SMEAR; SURVIVAL RATE; UGANDA; COMPLICATION; PNEUMONIA; STATISTICS AND NUMERICAL DATA;

CORYNEBACTERINEAE; FUNGI; PNEUMOCYSTIS JIROVECII;

ADULT; FEMALE; HIV INFECTIONS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; PROSPECTIVE STUDIES; UGANDA;

EID: 84930622649     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126591     Document Type: Article

References (36)

1. Curtis AJ, Marshall CS, Spelman T, Greig J, Elliot JH, Shanks L, et al. Incidence of WHO stage 3 and 4 conditions following initiation of anti-retroviral therapy in resource limited settings. PLoS One. 2012; 7 (12):e52019. doi: 10.1371/journal.pone.0052019 PMID: 23284857
2. Marshall CS, Curtis AJ, Spelman T, O'Brien DP, Greig J, Shanks L, et al. Impact of HIV-associated conditions on mortality in people commencing anti-retroviral therapy in resource limited settings. PLoS One. 2013; 8(7):e68445. doi: 10.1371/journal.pone.0068445 PMID: 23935870
3. Feldman C, Glatthaar M, Morar R, Mahomed AG, Kaka S, Cassel M, et al. Bacteremic pneumococcal pneumonia in HIV-seropositive and HIV-seronegative adults. Chest. 1999; 116(1):107-14. PMID: 10424512
4. Hirschtick RE, Glassroth J, Jordan MC, Wilcosky TC, Wallace JM, Kvale PA, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med. 1995; 333(13):845-51. PMID: 7651475
5. Johnson DH, Carriere KC, Houston S, Jin Y, Predy G, Gill J, et al. Hospitalization for community-acquired pneumonia in Alberta patients with human immunodeficiency virus infections: a case control study. Can Respir J. 2003; 10(5):265-70. PMID: 12952006
6. Park DR, Sherbin VL, Goodman MS, Pacifico AD, Rubenfeld GD, Polissar NL, et al. The etiology of community-acquired pneumonia at an urban public hospital: influence of human immunodeficiency virus infection and initial severity of illness. J Infect Dis. 2001; 184(3):268-77. PMID: 11443551
7. Touchie C, Marrie TJ. Comparison of community-acquired pneumonia requiring admission to hospital in HIV-and non-HIV-infected patients. Can J Infect Dis. 1996; 7(4):253-8. PMID: 22514448
8. Sogaard OS, Lohse N, Gerstoft J, Kronborg G, Ostergaard L, Pedersen C, et al. Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study. Clin Infect Dis. 2008; 47(10):1345-53. doi: 10.1086/592692 PMID: 18834317
9. Sogaard OS, Lohse N, Gerstoft J, Kronborg G, Ostergaard L, Pedersen C, et al. Mortality after hospitalization for pneumonia among individuals with HIV, 1995-2008: a Danish cohort study. PLoS One. 2009; 4(9):e7022. doi: 10.1371/journal.pone.0007022 PMID: 19750011
10. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997; 336(4):243-50. PMID: 8995086
11. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003; 58(5):377-82. PMID: 12728155
12. Chew KW, Yen IH, Li JZ, Winston LG. Predictors of pneumonia severity in HIV-infected adults admitted to an Urban public hospital. AIDS Patient Care STDS. 2011; 25(5):273-7. doi: 10.1089/apc.2010.0365 PMID: 21488749
13. Cordero E, Pachon J, Rivero A, Giron JA, Gomez-Mateos J, Merino MD, et al. Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients: validation of severity criteria. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. Am J Respir Crit Care Med. 2000; 162(6):2063-8. PMID: 11112115
14. Sanders KM, Marras TK, Chan CK. Pneumonia severity index in the immunocompromised. Can Respir J. 2006; 13(2):89-93. PMID: 16550266
15. Zuberi FF, Khan JA. Prospective comparison of prediction rules of mortality risk for CAP in a developing country. Int J Tuberc Lung Dis. 2008; 12(4):447-52. PMID: 18371273
16. Arozullah AM, Parada J, Bennett CL, Deloria-Knoll M, Chmiel JS, Phan L, et al. A rapid staging system for predicting mortality from HIV-associated community-acquired pneumonia. Chest. 2003; 123 (4):1151-60. PMID: 12684306
17. Reed C, Madhi SA, Klugman KP, Kuwanda L, Ortiz JR, Finelli L, et al. Development of the Respiratory Index of Severity in Children (RISC) score among young children with respiratory infections in South Africa. PLoS One. 2012; 7(1):e27793. doi: 10.1371/journal.pone.0027793 PMID: 22238570
18. World Health Organization. Reduction of number of smears for the diagnosis of pulmonary TB. Geneva: World Health Organization, 2007.
19. Shtatland E, Cain E, Barton M. The perils of stepwise logistic regression and how to escape them using informational criteria and the output delivery system. SUGI. 2001;26.
20. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: Wiley; 2004.
21. Fei MW, Kim EJ, Sant CA, Jarlsberg LG, Davis JL, Swartzman A, et al. Predicting mortality from HIVassociated Pneumocystis pneumonia at illness presentation: an observational cohort study. Thorax. 2009; 64(12):1070-6. doi: 10.1136/thx.2009.117846 PMID: 19825785
22. Curran A, Falco V, Crespo M, Martinez X, Ribera E, Villar del Saz S, et al. Bacterial pneumonia in HIVinfected patients: use of the pneumonia severity index and impact of current management on incidence, aetiology and outcome. HIV Med. 2008; 9(8):609-15. doi: 10.1111/j.1468-1293.2008.00603.x PMID: 18557951
23. Manabe YC, Wang Y, Elbireer A, Auerbach B, Castelnuovo B. Evaluation of portable point-of-care CD4 counter with high sensitivity for detecting patients eligible for antiretroviral therapy. PLoS One. 2012; 7(4):e34319. doi: 10.1371/journal.pone.0034319 PMID: 22536323
24. Uganda Ministry of Health. National antiretroviral treatment and care guidelines for adults, adolescents, and children. Uganda Ministry of Health, 2008.
25. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization, 2013.
26. Uganda Ministry of Health. Addendum to the national antiretroviral treatment guidelines. Uganda Ministry of Health, 2013.
27. Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009; 4(5):e5575. doi: 10.1371/journal.pone.0005575 PMID: 19440326
28. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010; 362(8):697-706. doi: 10.1056/NEJMoa0905848 PMID: 20181971
29. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011; 365(16):1471-81. doi: 10.1056/NEJMoa1013911 PMID: 22010913
30. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011; 365(16):1482-91. doi: 10.1056/NEJMoa1013607 PMID: 22010914
31. Cox JA, Lukande RL, Nelson AM, Mayanja-Kizza H, Colebunders R, Van Marck E, et al. An autopsy study describing causes of death and comparing clinico-pathological findings among hospitalized patients in Kampala, Uganda. PLoS One. 2012; 7(3):e33685. doi: 10.1371/journal.pone.0033685 PMID: 22432042
32. Wong EB, Omar T, Setlhako GJ, Osih R, Feldman C, Murdoch DM, et al. Causes of death on antiretroviral therapy: a post-mortem study from South Africa. PLoS One. 2012; 7(10):e47542. doi: 10.1371/journal.pone.0047542 PMID: 23094059
33. 2011 Uganda AIDS Indicator Survey: Key Findings. Calverton, Maryland, USA: Uganda Ministry of Health and ICF International, 2012.
34. Fine MJ, Hanusa BH, Lave JR, Singer DE, Stone RA, Weissfeld LA, et al. Comparison of a diseasespecific and a generic severity of illness measure for patients with community-acquired pneumonia. J Gen Intern Med. 1995; 10(7):359-68. PMID: 7472683
35. Fine MJ, Orloff JJ, Arisumi D, Fang GD, Arena VC, Hanusa BH, et al. Prognosis of patients hospitalized with community-acquired pneumonia. Am J Med. 1990; 88(5N):1N-8N. PMID: 2195886
36. Fine MJ, Singer DE, Hanusa BH, Lave JR, Kapoor WN. Validation of a pneumonia prognostic index using the MedisGroups Comparative Hospital Database. Am J Med. 1993; 94(2):153-9. PMID: 8430711